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Abstract
Chagas’ disease affects millions in Latin America and is the leading cause of cardiomyopathy and death due to cardiovascular disease in
patients aged 30–50 years. As a consequence of immigration it has settled in several European countries, where besides imported cases,
autochthonous infections arise through vertical transmission and blood/organ donation. All Latin American immigrants who attended
our Unit were screened for T. cruzi infection (ELISA and IFAT ± PCR). An ECG and echocardiogram were requested for all positive
patients, and oesophageal manometry, barium swallow and barium enema were requested according to patient symptoms. All patients
under 50 years without severe cardiac involvement and who had not received correct treatment previously were treated with benzni-
dazole 5 mg/kg/day for 60 days. Patients were followed-up with serology and PCR 1 month after treatment ended and every 6 months
thereafter. A total of 1146 Latin Americans were screened for T. cruzi (357 positive serology results). The typical patient proﬁle was a
Bolivian female, of rural origin, in her fourth decade of life, without evidence of visceral involvement. Treatment tolerance was poor,
with 29.7% discontinuing treatment due to adverse reactions. Among those with adverse reactions (52%), the most frequent were cuta-
neous hypersensitivity (68.7%), gastrointestinal upset (20%) and nervous system disturbances (16.2%). T. cruzi infection is no longer lim-
ited to Latin America. Poor treatment tolerance can limit current treatment options. More epidemiological data are necessary to
estimate the magnitude of a problem of great relevance for public health and health resource planning.
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Introduction
One hundred years after the discovery of Chagas’ disease, it
still affects millions in Latin America and is the leading cause
of cardiomyopathy and death due to cardiovascular disease
in patients aged 30–50 years [1]. Although the burden of the
disease has decreased in the last years due to different con-
trol measures, thousands of new cases are being diagnosed
each year [2] and many challenges still need to be overcome
before its successful elimination. One of the main compo-
nents of a good strategy would be better monitoring and
estimation of disease burden worldwide [3].
In endemic areas, vectorial transmission accounts for over
80% of cases. However, with the recent increase in migra-
tion from Latin America to western countries, other modes
of transmission are becoming increasingly more important.
Those who migrate seeking work opportunities and to
improve their quality of life are usually healthy, and younger
than the general population. Most Latin Americans will have
been infected during childhood and therefore, based on the
natural course of the disease, these migrants would now be
at an age when the ﬁrst manifestations of cardiac involve-
ment may be expected to appear.
Imported Chagas’ disease has already been recognized as an
emerging problem in the USA [4] and this has now reached
Europe and, in particular, Spain [5–7]. In many European coun-
tries, Chagas’ disease has now become a frequent reason for
consultation, especially at specialized tropical medicine units,
whilst previously this disease was practically unknown in these
areas. The potential severity of the disease in certain patients,
even if initially asymptomatic, should not be dismissed [8,9].
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The objective of this study was to describe the clinical-epi-
demiological characteristics of the largest cohort of Latin
American immigrants with chronic T. cruzi infection
described in Europe to date, as well as providing preliminary
data on response to and tolerance of treatment with benzni-
dazole.
Materials and Methods
Study design
This was a prospective, observational study performed at the
Tropical Medicine Unit (TMU), Infectious Diseases Depart-
ment, of the Ramo´n y Cajal Hospital in Madrid, Spain during
a 7-year period (2003–2009). All immigrants from Central or
South America who attended our Unit were screened for
T. cruzi infection.
Diagnosis of Chagas disease
Chagas’ disease was diagnosed in patients with two posi-
tive serological tests enzyme-linked immunosorbent assay
and indirect immunoﬂuorescence assay (ELISA and IFAT)
against different parasite antigens. Polymerase chain reac-
tion PCR was requested for all patients with positive
serology (in-house PCR using 121-122 and Tczl-Tcz2 oligo-
nucleotides) [10]. A baseline ECG and echocardiogram
(ECC) were requested for all patients, and oesophageal
manometry, barium swallow and barium enema were
requested according to individual patient symptoms.
The following symptoms were considered suggestive of
Chagas’ disease once other causes were excluded. Cardiac
[11]: palpitations, syncope, fatigue, dyspnoea on exertion,
oedema or atypical chest pain. Gastrointestinal [12]: dysphagia
with odynophagia, epigastric pain, regurgitation, ptyalism and
malnutrition in severe cases of mega-oesophagus and pro-
longed constipation in megacolon.
The following criteria were used to diagnose visceral
involvement due to Chagas’ disease. ECG [2]: complete right
bundle branch block (RBBB) in isolation or associated with
left anterior hemiblock, complex ventricular arrhythmias and
sustained ventricular tachycardia, supraventricular tachyar-
rhythmias, type II second degree and complete A–V blocks,
sinus bradycardia <50 beats per minute and presence of a
permanent pacemaker. Echocardiogram [11]: left ventricular
(LV) dysfunction with decreased ejection fraction (LVEF) and
increased LV diastolic diameter, wall movement abnormali-
ties, apical aneurysm or presence of thrombus within a car-
diac cavity, with no other justiﬁable cause. Oesophageal
manometry [13]: aperistalsis, non-relaxing or partially relaxing
lower oesophageal sphincter (LEE). Barium swallow [13]: slow
transit, retention of contrast, oesophageal dilatation or dolic-
omegaesophagus. Barium enema [13]: dolichocolon or mega-
colon.
Treatment and follow-up
All patients under 50 years, without severe cardiac involve-
ment and who had not received correct treatment previ-
ously in their country of origin were treated with
benznidazole 5 mg/kg in two to three divided doses daily for
60 days [14,15]. We also offered treatment to those above
50 years without severe cardiac involvement, after explaining
the risks and beneﬁts of therapy. From September 2009,
those patients who stopped treatment early due to side-
effects were treated with nifurtimox with gradually increasing
doses to reach a maintenance dose of 8–10 mg/kg/day for
90 days. Patients were considered to have been adequately
treated when the drug was taken for at least 1 month.
Once treatment was started, patients were seen after
2 weeks and at the end of treatment in order to ascertain
treatment adherence, tolerance and toxicity. Full blood count
and biochemistry tests were also performed at these times.
T. cruzi serology and PCR were performed 1 month after
treatment ended and every 6 months thereafter. An ECG was
performed annually in the absence of new symptoms suggest-
ing cardiac involvement. Treatment was considered successful
when a disappearance of antibodies using serological tests was
observed. Patients with persisting antibodies following treat-
ment were considered to have an as yet undetermined
response to treatment (due to the short duration of follow-
up in some patients). Treatment was considered to have failed
when persistence of the parasite was detected by PCR [2].
Adverse effects were classiﬁed according to the Cancer
Therapy Evaluation Program, Common Toxicity Criteria,
Version 2.0 [16]. In the case of milder adverse effects the
discontinuation of treatment was discouraged if possible but
benznidazole was stopped in cases of clear intolerance or
severe adverse events, particularly signiﬁcant leucopoenia
(<2500 cells/mm3), peripheral neuropathy or severe allergic
dermopathy.
Baseline characteristics were analysed using descriptive
statistics. Qualitative variables were expressed as absolute
frequencies and percentages, and quantitative variables as the
median and interquartile range (IQR). Categorical variables
were compared using the chi-square or Fisher exact test,
and continuous variables by the t-test or Mann–Whitney
U-test. Survival curves were calculated using the Kaplan–
Meier method and differences were evaluated using the
log-rank test. A p value <0.05 was considered signiﬁcant. SPSS
(Chicago, IL, USA) software package version 15.0 was used
for statistical analysis.
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The local ethics committee approved the study protocol
and database registry. Patients were included after an
informed consent form was signed.
Results
A total of 2125 immigrants from all over the world were
seen during the study period. A signiﬁcant increase in the
number of patients screened for T. cruzi was observed from
2003 (18 patients) to 2009 (408 patients) (b = 73; IC 95%:
31–114; p 0.007). T. cruzi serology was performed for 1146
Latin American patients; this was positive in 357 (31%). Out
of 337 PCR tests (20 patients did not have baseline PCR
results but for some patients more than one PCR was per-
formed), 212 patients (63%) had one or both positive PCRs.
Serology and PCR results for the total number of individuals
screened is shown in Table 1.
Of those with positive T. cruzi serology, 146 (41%) were
referred to the TMU from other health centres (other hos-
pitals, primary care centres or transfusion centres), 103
(29%) were recruited following speciﬁc campaigns, 99 (28%)
were self-referred and 9 (2%) attended due to clinical symp-
toms. At the time of the ﬁrst visit the median duration of
residence in Spain was 3.4 years (interquartile range 2.3–5.2).
The median age was 36 years (interquartile range 29–44),
346 (97%) were from Bolivia, three from Paraguay, two from
Argentina, two from Brazil, two from Ecuador, one from
Honduras and one was from Chile, and 241 (67.5%) were
female. In total, 83.5% recalled having seen the vector in
their homes, and 78.7% had lived in rural areas. Two hun-
dred and nine (59%) patients had a relative with Chagas dis-
ease and for 64 of them vertical transmission was a
possibility (mother with Chagas’ disease). Thirty-six (10%)
patients had received a previous blood transfusion.
A total of 168 (47%) patients had previous positive serol-
ogy (mostly performed at transfusion centres in Bolivia), but
only 33 of them had received previous anti-trypanosomal
treatment and none appeared to have received a complete
course. Five of them (15.2%) had a positive PCR result
before starting therapy with benznidazole in our Unit.
Clinical data were available for 252 patients (27 were lost
to follow-up and for 78 patients tests were still being com-
pleted at the end of the study period). Visceral involvement
was diagnosed in 56/252 patients (22.2%): 43 (17.1%) had
cardiac involvement, nine (3.5%) had gastrointestinal involve-
ment and four (1.6%) had both. There were no signiﬁcant
differences in visceral involvement by sex (p 0.21).
Out of 47 patients with cardiomyopathy, one died due to
an acute myocardial infarction, one was a heart transplant
recipient (due to dilated cardiomyopathy), two were awaiting
cardiac transplantation (dilated cardiomyopathy), two had
pacemakers (due to complete A-V blocks), 12 had evidence
of cardiomyopathy on ECC and 29 had ECG abnormalities
suggestive of Chagas’ disease (mainly complete RBBB in isola-
tion or associated with left anterior hemiblock). Of the 13
patients with gastrointestinal involvement, one had megacol-
on and megasigma, three had abnormalities on oesophageal
manometry suggestive of Chagas’ disease, four had dolicho-
megacolon and ﬁve had dolichosigma.
Eleven women were pregnant and there were no cases of
vertical transmission. Four patients were infected with HIV,
all asymptomatic, with an adequate immunological status and
with no documented reactivation of Chagas’ disease. Three
of them had a negative PCR result and one a positive one.
Out of those 252 patients for whom clinical data were
available, 195 patients received treatment with benznidazole
(12 of them were above 50 years old and preferred to take
the treatment) and the remaining 57 were pending initiation
of treatment at subsequent visits. One hundred and four
completed the treatment course without signiﬁcant adverse
events, or with mild adverse events that did not lead to treat-
ment discontinuation. Eleven discontinued benznidazole due
to adverse events but were considered to have received a
complete course as they took the treatment for at least
1 month. Of the remaining 80 patients: 30 received <1 month
of treatment (discontinued due to side-effects) and 50 were
still completing the treatment at the end of the study period.
A safety and tolerability analysis was performed on 148
out of 195 patients (those patients who had completed
treatment or had already discontinued it due to adverse
reactions at the end of the study period were included in
the analysis). In total, 77/148 (52%) patients had documented
adverse reactions (Table 2). Of these, 44/148 (29.7%)
stopped treatment even though side-effects were mild. Med-
ian time to interruption was 22 days (95% CI 9–34). Age,
sex and HIV infection were not signiﬁcantly associated with
the occurrence of adverse reactions or treatment interrup-
tions. Among the 77 patients who developed toxicity, the
most common side-effects were cutaneous toxicity (morbilli-
form rash, pruritus and occasional mucosal involvement) in
68.7%, gastrointestinal symptoms (nausea, vomiting, gastric
pain and anorexia) in 20%, and nervous system disturbances
TABLE 1. Serology and PCR results for the total number of
individuals screened
n
Number of
positives (%)
Individuals screened by serology 1146 357 (31)
Individuals with PCR performed 337 212 (63)
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(headache, anxiety, dizziness, disesthesias or paresthesias) in
16.2%. Five patients (6.5%) developed mild leucopoenia and
two had taste disturbances (2.6%).
We investigated whether benznidazole dosing was related
to the incidence of adverse reactions or treatment discontin-
uation in two ways: according to whether dose was £ or
>300 mg daily, and according to total daily dose. There was
no signiﬁcant association between benznidazole dose (£ or
>300 mg daily) and the occurrence of adverse reactions
(v2 = 0.018; p 0.89), the severity of reactions (v2 for
trend = 1.46; p 0.69), or treatment discontinuation
(v2 = 0.67; p 0.41). Total daily dose was not associated with
the occurrence of adverse reactions (p 0.73), the severity of
reactions (p 0.98), or treatment discontinuation (p 0.18). For
the three patients who received nifurtimox as second-line
treatment, this was well tolerated in all cases.
Median follow-up after treatment was 1 year (IQR 0.3–2).
For eight patients, T. cruzi antibody levels decreased follow-
ing treatment, but none of the serologies became negative
during the study period. In 70 cases, there was no docu-
mented fall in antibody levels. In the 65 patients with a posi-
tive pre-treatment PCR this became negative following
treatment in all of them.
Discussion
There has been a recent increase in the number of patients
with Chagas’ disease outside areas classically considered
endemic for the disease, particularly in Spain where, until
recently, the disease was hardly ever diagnosed [17]. A sero-
prevalence of 31% was found in our study population. This
high prevalence may have been partly due to selection bias,
as TMU is a specialized referral centre with screening pro-
grammes for Chagas’ disease, which also include testing
patients’ relatives. However, studies performed at other
Spanish referral centres have described similar seropreva-
lence rates (34% [8] and 41% [9]). The patients included in
this study may well be at higher risk for the infection as
most of them were from Bolivia (currently the Latin Ameri-
can country with the highest prevalence rates), from rural
areas, where the majority were exposed to the vector and
had affected family members.
A signiﬁcant increase in the number of T. cruzi serologies
performed has also been documented during the period
2003–2009. This trend will probably be maintained in the
future irrespective of migration ﬂuxes, as only a minority of
immigrants residing in our country have so far been tested
for Chagas’ disease. In fact, the majority of patients in the
cohort had been residing in Spain for several years (median
duration of residence, 3.4 years).
The rates of visceral involvement were slightly lower than
those observed in the literature: 18.6% cardiac involvement
and 5.1% gastrointestinal involvement in our study, vs. 20–
30% and 10%, respectively [18]. These ﬁgures could increase
in the future, taking into account that the median age of the
patients was 36 years (similar to that described in other
Spanish studies) [8] and that the majority come from rural
areas, were probably infected during childhood and that vis-
ceral damage develops 20–30 years after the infection. The
rates of visceral involvement found in immigrants, therefore,
are not very different to those found in patients in endemic
areas.
Benznidazole is the most widely used drug for treatment,
but, although consensus of expert opinion maintains that
aetiological treatment should be offered to all patients
under 50 years with reactive T. cruzi serology and without
evidence of advanced cardiomyopathy [14,19], there is
weak evidence supporting its use in the chronic phase of
the infection [15]. In our study all patients who met these
two criteria were treated and we also offered treatment to
those older than 50 years. Tolerance, in general, was poor,
with a frequency of adverse reactions equivalent to that
described in other studies (52% vs. 50%). Nevertheless, the
proportion of adverse effects due to cutaneous hypersensi-
tivity was higher than previously reported (68.7% vs. 20–
25%) [20]. Even though most adverse effects were not
severe, a large proportion of our patients decided to stop
treatment (29.7%), mainly due to pruritus/cutaneous lesions,
thus limiting treatment options [21]. Even though some
authors postulate that benznidazole dose may be associated
with the appearance of adverse effects, we found no
statistically signiﬁcant differences when different doses were
considered.
Nifurtimox has a similar efﬁcacy proﬁle to benznidazole,
but is associated with a higher incidence of side-effects
(40 –97%) [22]. Nevertheless, if one drug is ineffective or
must be discontinued, the other can be used as an alterna-
tive [12]. In our cohort only a few patients were treated
TABLE 2. Adverse reactions related to benznidazole treat-
ment
Patients who could be evaluated in the safety analysis 148
Patients with any adverse reaction (%) 77 (52.0)
Grade 1 36 (24.3)
Grade 2 33 (22.3)
Grade 3 7 (4.7)
Grade 4 1 (0.7)
Treatment discontinuation due to adverse reactions (%) 44 (29.7)
Treatment discontinuation due to adverse reactions
<30 days of therapya (%)
33 (22.3)
aTreatment considered incomplete.
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after benznidazole intolerance with nifurtimox and even
though no hypersensitivity reactions were documented more
data would be needed in order to draw any signiﬁcant con-
clusion. Promising studies with new molecules are currently
under way [23,24], but for the time being treatment options
for T. cruzi are very limited.
During the study period, no patients could be considered
to have been cured as antibody titres did not decrease sig-
niﬁcantly or become negative [25]. However, the fall in
antibody titres has been described to occur 5 years follow-
ing treatment [2], and this period may vary depending on
age and the phase of the illness, so a greater decrease in
antibody levels may be expected during the next few years
of follow-up. On the other hand, PCR became negative fol-
lowing treatment in all those patients who had a positive
PCR pretreatment, so none of the treatments could be
considered to have failed either. The value of PCR relies
mainly on positive results, and it may be useful as an early
marker of resistance to chemotherapy years before serol-
ogy [26]. It is important to remember that a negative PCR
does not guarantee parasitological cure, as parasitaemia
may ﬂuctuate in the chronic phase of the infection so it
may become positive after a longer time of follow-up
[25,26]. Although not currently available, ﬂow cytometry
may be a useful tool to demonstrate cure in the near
future [27].
T. cruzi infection is no longer limited to the Latin Ameri-
can continent and has currently emerged in certain non-
endemic areas such as the USA and western Europe. In Spain
the majority of patients are female Bolivian immigrants in the
fourth decade of their lives, who can transmit the infection
through blood transfusion, organ transplantation or congeni-
tal transmission. Treatment tolerance is poor, which can fur-
ther limit current treatment options. Sound epidemiological
data are necessary in order to estimate the magnitude of a
problem of great relevance for public health and health
resource planning.
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